BTIG initiated coverage of Bright Minds (DRUG) with a Buy rating and $72 price target The company is developing a “very specific” 5-HT2C agonist, BMB-101, for epilepsies that has better dosing than bexicaserin, the analyst tells investors in a research note. The firm believes the dosing advantage is relevant given data suggesting the side effects of the 5-HT2C class may be peak concentration-dependent. The relatively high percentage of absence seizures in otherwise healthy children suggests convenient dosing and low side effects “are a major positive,” contends BTIG. It expects Phase 2 data from Bright Minds around year-end 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRUG:
- Bright Minds Biosciences Launches $100 Million At-The-Market Offering
- Psychedelic: Bright Minds reports preclinical BMB-201 results
- Bright Minds says BMB-201 outperforms sumatriptan in preclinical model
- Bright Minds Biosciences: Advancing Breakthrough Epilepsy Treatment with BMB-101 and Strong Financial Position
- Bright Minds Biosciences Reports Q3 2025 Financial Results